Journal of Neuroinflammation

BackgroundTraumatic brain injury (TBI) is increasingly recognized as a chronic condition with lasting systemic consequences. Beyond persistent neuroinflammation, long-term TBI disrupts peripheral immune homeostasis, increasing susceptibility to infection and organ dysfunction, particularly in older patients. The voltage-gated proton channel Hv1, expressed in microglia and peripheral immune cells, regulates oxidative injury via modulation of NADPH oxidase activity. Yet few animal studies extend long enough to recapitulate the lifelong trajectory of human TBI, leaving the long-term effects of Hv1 deficiency on systemic immune homeostasis unresolved. MethodsYoung adult (3-month-old) male wild-type (WT) and Hv1 knockout (Hv1KO) mice were subjected to a moderate controlled cortical impact (CCI), and survival was monitored for up to 18 months post-injury, with endpoint analyses performed at 21 months of age. After neurological behavioral assessments, spleen, lung, liver, gut, ipsilateral cortex, and blood samples were collected for flow cytometry, qPCR, NanoString nCounter Panels, and in vivo plasma transfer studies. ResultsHv1 deficiency resulted in significantly increased mortality following TBI, starting at 14 months post-injury, compared with WT/TBI mice. No significant difference in survival was observed between the two sham groups. At 18 months post-injury, Hv1KO mice exhibited significant weight loss and splenomegaly. qPCR revealed an approximately 30-fold increase of pan-bacterial 16S rRNA levels in the spleens of Hv1KO/TBI mice, but not in the lungs or liver. Furthermore, chronic TBI in the Hv1KO mice led to a compromised intestinal tight junction and mucus barrier integrity, accompanied by aberrant activation of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway in the spleen. Transcriptomic profiling of the spleen, liver, and lung revealed distinct post-injury immune signatures in Hv1KO mice. In contrast, surviving Hv1KO/TBI mice showed modest behavioral resilience and a partially neuroprotective cortical transcriptomic profile. Lastly, systemic transfer of plasma from WT/TBI or Hv1KO donors into naive young adult mice altered immune responses in the spleen, lung, and brain. ConclusionsHv1 plays a critical role in maintaining peripheral immune integrity and antibacterial defense throughout the chronic course of TBI. Despite conferring modest neuroprotection through attenuation of microglial-mediated oxidative stress, Hv1 deficiency exacerbated systemic phagocyte dysfunction and significantly reduced long-term survival.

Brain development, especially developmental myelination, continues through young adulthood. Concordantly, children may be particularly vulnerable to neural-immune challenges. To investigate the consequences of major childhood immune challenges, juvenile mice were exposed to respiratory influenza (H1N1) infection. White matter-specific microglial reactivity accompanied by oligodendrocyte loss was evident until two months following infection. Mice exhibited hyperlocomotion and impaired attention, but not anxiety-like behavior, at one month following infection. Linking the oligodendroglial and behavioral deficits, genetic disruption of oligodendrocyte development at the same juvenile timepoint recapitulated this behavioral phenotype. Microglial reactivity and oligodendrocyte numbers normalized by young adulthood. However, myelin development was disrupted, with persistently decreased myelinated axon density and reduced myelin sheath thickness. Hyperlocomotion resolved, but anxiety-related behaviors emerged at two months after infection. At 6 months, anxiety resolved but cognitive deficits persisted. Elevated CSF chemokines and microglial chemokine expression prompted testing the role of the multi-chemokine receptor CCR3. CCR3 inhibition rescued these cellular and behavioral aberrations after juvenile H1N1 infection. Together, these findings underscore the potential for disruption of myelin development and lasting cognitive and neuropsychiatric sequelae following major immune challenges during the juvenile period and highlight chemokine signaling as an important therapeutic target.

Microglia are essential immune cells of the brain parenchyma which are responsible for maintaining homeostasis and responding to brain injury. When activated, they induce immune signaling and become phagocytic. In the context of neurodegenerative diseases, they exhibit both pro- and anti-inflammatory properties. Human endogenous retroviruses (HERVs) are the remnants of ancient retroviral germline infections that integrated into the human genome, and their expression has been directly linked to microglial-mediated neurodegenerative diseases. Despite this, HERV expression is not consistently included in analyses characterizing microglia. Investigating the function of microglia across different diseases is critical for elucidating mechanisms of disease progression and for the development of effective therapeutic interventions. Approaches to studying microglia include isolation from post-mortem brain tissues, differentiation from peripheral blood monocytes or differentiation of induced pluripotent stem cells (iPSC). Ex vivo brain derived microglia (BdMG) are considered most physiologically relevant, but constraints including the unpredictable timing of availability, labor-intensive protocols, and low yields reduce their practicality. Existing alternatives are iPSC-derived microglia (iMG) and monocyte-derived microglia (MDMi) models that circumvent sample accessibility and scalability issues. Here, we explored the transcriptome and proteome of these three microglia sources and identified a common microglia surface marker expression profile, establishing that MDMi and iMG exhibit similar phenotypes relative to BdMG. We also identified a common HERV expression profile across BdMG, iMG and MDMi, indicating deeper similarities across different sources. Altogether, our findings indicate that given the phenotypic similarities of the 2 models, MDMi represent a practical and reliable model for investigating microglial function with iMG models serving for more molecular based approaches, such as CRISPRa/i.

Brain tuberculosis remains associated with high mortality, and many survivors exhibit cognitive impairments. Progress in understanding the disease is hindered by the lack of human models. In this study, human neural organoids were infected, revealing that a subpopulation of neural progenitor cells (NPCs) is directly infected by apoptotic cell receptors expressed by NPCs, mediating bacterial uptake. Phagocytosed bacteria were localized in late endosomes, lysosomes, and the cytoplasm. Cytoplasmic bacteria frequently formed cords, indicating limited control of bacterial expansion. Immunostaining demonstrated that infected NPCs produce a type I interferon (IFN) response, corroborated by increased expression of type I IFN and IFN-regulated genes detected by RNA sequencing. Pathways related to innate immune response, cell death, and proliferation were also activated following Mycobacterium tuberculosis (Mtb) uptake by NPCs. The addition of color-coded microglia and monocytes to 3D neural organoids and NPCs revealed cross-infection of NPCs and other phagocytes by Mtb, suggesting a mechanism by which NPCs may access the bacteria. Infection of NPCs resulted in increased cell death, inhibition of neural differentiation, and reduced proliferation, effects that were partially mitigated by anti-IFN treatment. Differentiated neurons were not infected. These findings indicate that brain organoids and NPC-based in vitro platforms provide a novel approach for studying brain tuberculosis. Decreased NPC function may contribute to brain tuberculosis-induced cognitive disease.

Atypical chemokine receptors (ACKRs) regulate inflammatory responses by scavenging and sequestering chemokines. The Duffy antigen receptor for chemokines (DARC), also known as ACKR1, binds multiple inflammatory chemokines and regulates inflammation in peripheral tissues. However, the distribution and functional role of DARC/ACKR1 in the brain remain to be defined. Here, we show that DARC/ACKR1 is widely expressed throughout the mouse brain, with marked regional heterogeneity. DARC/ACKR1 is predominantly expressed by neurons and is not detected in microglia or astrocytes. Importantly, this neuronal expression pattern was also observed in the human brain. Furthermore, DARC/ACKR1 deficiency resulted in enhanced neuroinflammation, characterized by increased microglial activation and astrogliosis across multiple brain regions, particularly the hippocampus, and was accompanied by cognitive deficits. Together, these findings identify DARC/ACKR1 as a previously unrecognized neuron-specific atypical chemokine receptor that plays an important role in restraining neuroinflammation and preserving cognitive function.

Microglia, the resident immune cells of the central nervous system, undergo dynamic transcriptional remodeling across embryonic and postnatal development. However, the precise transcriptional programmes governing these transitions, and the role of oxidative stress pathways such as NRF2/Hmox1 in shaping microglial maturation, remain incompletely understood. Here, we characterized the transcriptional landscape of mouse microglial development using pseudobulk RNA-sequencing data, spanning five developmental stages, from embryonic day 17 to postnatal day 60. We identified four distinct transcriptional programmes (homeostatic, phagocytic, NRF2/Hmox1 oxidative stress-responsive, and Apoc1-associated) whose relative activities shift coordinately across development. Early developmental microglia were dominated by phagocytic and NRF2/Hmox1-associated gene expression, while mature microglia progressively acquired a homeostatic transcriptional identity marked by Tmem119 and P2ry12. Pseudotime trajectory analysis confirmed a continuous developmental axis along which the phagocytic programme declined, homeostatic programme increased, and NRF2/Hmox1 activity peaked at intermediate stages. Differential expression analysis distinguished Tmem119+ homeostatic microglia from Tmem119- populations, and early developmental from mature microglial states. Additionally, chemokine receptor expression, including Cxcr4 at early timepoints, suggested a role for chemokine signaling in microglial migration and tissue integration during brain development. Collectively, these findings support a model in which microglial maturation proceeds along a transitional regulatory role during brain development.

Microglial activation is a central component of neuroinflammatory responses in many brain pathologies. Increasing evidence indicates that microglial phenotype is tightly linked to cellular metabolism, with pro-inflammatory activation associated with enhanced glycolytic flux. Lactate, traditionally considered a metabolic substrate, has recently emerged as a signaling molecule capable of modulating immune responses. However, its direct impact on microglial inflammatory activation remains incompletely understood. In the present study, we investigated the effects of lactate on microglial phenotype under inflammatory conditions using primary rat microglial cultures stimulated with lipopolysaccharide (LPS). Microglial activation was assessed through the expression of phenotypic markers, cytokine production, and secreted chemokine profiles. LPS stimulation induced a strong pro-inflammatory response characterized by increased CD86 expression, elevated TNF-alpha secretion, and enhanced release of several pro-inflammatory chemokines. Post-treatment with sodium L-lactate significantly attenuated these inflammatory responses, reducing pro-inflammatory marker expression and cytokine secretion, while restoring the anti-inflammatory marker CD206. To explore the relevance of these findings in a pathological context, the effects of lactate were further examined in a neonatal rat model of hypoxia-ischemia. Sodium L-lactate administration after injury reduced microglial activation and promoted a shift toward an anti-inflammatory phenotype in cortical regions, whereas hippocampal microglia showed a more limited response. Together, these results demonstrate that lactate directly modulates microglial inflammatory activation and cytokine production in vitro and suggest that lactate-mediated metabolic signaling may contribute in vivo to the regulation of neuroinflammatory responses.

Age-dependent variation in the immune response is a critical determinant of host susceptibility, disease severity, and long-term sequelae in coronavirus infections, a principle strikingly demonstrated by the COVID-19 pandemic caused by SARS-CoV-2. Although primarily pneumotropic, coronaviruses carry significant neurotropic potential, driving neurological complications whose severity is profoundly determined by host age. Elderly individuals and often children suffer disproportionately severe disease, whereas young adults relatively mount protective responses; yet the cellular and molecular determinants of this age-dependent neuroprotection remain poorly characterized. Using juvenile and young-adult C57BL/6 mice intracranially inoculated with {beta}-coronavirus MHV-RSA59, a murine equivalent of human coronaviruses, we examined immune dynamics at days 5 (innate-acute), 7 (innate-to-adaptive transition), and 30 (chronic) post-infection. Young-adult mice exhibited only occasional demyelination, in stark contrast to the extensive demyelination observed across all spinal cord levels in juveniles. This differential outcome was attributable to enhanced age-dependent immune maturation, characterized by efficient T cell-microglia/macrophage crosstalk enabling effective viral control by day 7 post-infection. Young adults displayed greater glial activation, heightened cytokine release, CX3CR1+ microglia activation, and augmented CNS trafficking of CX3CR1+ and MHC II+ monocytes/macrophages, IFN-{gamma}+ CD4+/CD8+ T cells, and CXCR3+ effector T cells relative to juveniles. Reduced naive T cell frequencies and elevated effector/central memory T cell populations in cervical lymph nodes further indicate a robust adaptive memory response conferring long-term protection. Additionally, greater regulatory T cell accumulation in young adults facilitates timely suppression of excessive neuroinflammation as viral burden subsides. Together, these findings define the age-dependent immune landscape that underpins neuroprotection in {beta}-coronavirus infection.

Vascular cognitive impairment and dementia (VCID) is increasingly recognized as a major contributor to cognitive decline; however, the mechanisms through which vascular dysfunction drives innate immune dysregulation remain poorly understood. In this study, we explore the impact of VCID on the cerebral innate immune landscape, focusing on innate lymphoid cells (ILCs) and neutrophils, two key players in neuroinflammation and brain immune homeostasis. Using a murine model of VCID induced by bilateral common carotid artery stenosis (BCAS) with modifications in C57BL/6 mice, we investigated innate immune cell distribution, polarization, and functional profiles using flow cytometry and immunofluorescence staining. Our findings reveal a compartment-specific shift in ILC populations, with a reduction of ILC2s in the meninges and concurrent expansion in the choroid plexus, accompanied by altered cytokine production. Furthermore, VCID drove a marked shift in neutrophil polarization toward a pro-inflammatory N1-like phenotype in both the meninges and choroid plexus. Critically, immunofluorescence staining of hippocampal brain sections confirmed that activated N1-like neutrophils, characterized by elevated IL-1{beta} and MPO and reduced IL-10, infiltrate the hippocampal parenchyma in VCID, suggesting a spatially progressive innate immune response spanning from CNS border compartments to brain tissue. These results identify a novel innate immune signature in VCID, compartment-specific ILC redistribution, pro-inflammatory neutrophil polarization at CNS borders, and parenchymal neutrophil infiltration in the hippocampus, which may collectively amplify neuroinflammation and accelerate cognitive decline, identifying potential therapeutic targets for vascular-related dementia.

Repetitive traumatic brain injury (rTBI) induces persistent microglial activation and chronic neuroinflammation, yet the upstream signals driving long-term synaptic injury remain unclear. In this study, we identify the CCL20-CCR6 chemokine axis as a critical regulator of sustained microglial activation and complement-dependent synaptic loss after rTBI. Proteomic profiling at 30 days post-injury (dpi) showed broad normalization of complement-linked inflammatory and synaptic pathways in the cortex and hippocampus, underscoring a mechanistic link between chemokine signaling, microglial activation, and synaptic vulnerability. To therapeutically target this axis, we developed a dendrimer-based shRNA platform (shCombo-DPX) that simultaneously silences CCL20 and CCR6. Intranasal and intravenous delivery in rTBI mice effectively reduced CCL20-CCR6 expression, attenuated chronic microgliosis and astrogliosis, and suppressed complement activation. Treatment limited microglial synaptic engulfment, preserved synaptic proteins, restored BDNF levels, and improved motor, anxiety-related, and cognitive outcomes. In microglia-neuron coculture systems, CCL20 silencing reduced LPS-induced complement signaling and prevented synaptic loss, neuronal apoptosis, and BDNF depletion. Conversely, exposure to recombinant CCL20 induced dendritic degeneration, caspase-3 activation, microglial reactivity, complement dysregulation, and synaptic injury both in vitro and in vivo. Collectively, these findings establish CCL20-CCR6 as a key upstream driver of chronic complement-mediated synaptic degeneration after rTBI and support dendrimer-delivered shRNA therapy as a targeted strategy to mitigate long-term neurodegeneration.

Reactive astrogliosis is a prominent feature of prion diseases, yet the molecular mechanisms regulating astrocyte activation and their contribution to disease progression remain poorly understood. Signal transducer and activator of transcription 3 (Stat3) is a master regulator of reactive astrocytes in numerous neurological disorders, but its role in prion disease has not been established. Here, we investigated the contribution of astrocytic Stat3 signaling to prion pathogenesis using an inducible astrocyte-specific Stat3 knockout mouse model. Stat3 expression was elevated across multiple neuroinflammatory conditions but was most strongly induced during prion disease. Among four mouse-adapted prion strains (ME7, RML, 22L, and SSLOW), the magnitude of Stat3 activation closely paralleled the severity of neuroinflammation. Astrocyte-specific Stat3 deletion was evaluated in mice infected with either the highly inflammatory SSLOW strain or the less inflammatory 22L strain. Stat3 deletion had no detectable effect on disease progression in SSLOW-infected mice but modestly delayed disease onset and behavioral decline in male mice infected with the 22L strain, particularly when knockout was induced before prion inoculation. Despite its limited effect on survival, astrocyte-specific Stat3 deletion consistently attenuated astrocyte reactivity, as evidenced by reduced vimentin expression, delayed cortical GFAP induction, and lower GFAP expression in recombined astrocytes at the single-cell level, demonstrating a cell-autonomous role for Stat3 in promoting reactive astrogliosis. In contrast, PrPSc accumulation and overall microglial activation remained unchanged, indicating that astrocytic Stat3 signaling is dispensable for prion replication and does not substantially influence the global microglial response. Tamoxifen-induced recombination occurred in only 40-70% of astrocytes, resulting in partial and region-dependent Stat3 deletion that likely underestimated the impact of astrocytic Stat3 loss. Together, these findings identify Stat3 as an important regulator of astrocyte reactivity during prion disease but demonstrate that its contribution to disease progression is limited and highly context-dependent, varying with the inflammatory milieu, timing of pathway inhibition, and biological sex. Our results highlight the redundancy of inflammatory signaling networks driving chronic prion neurodegeneration and suggest that targeting astrocytic Stat3 alone is unlikely to substantially alter disease progression.

Sickness is an organismal response to inflammation, yet its immune, metabolic, neural, and behavioral components are often studied separately and predominantly in male C57BL/6 mice. In this study, we characterized these responses to systemic lipopolysaccharide (LPS) in female BALB/c mice. Mice received intraperitoneal LPS at moderate concentrations and outcomes were assessed during the acute and resolving phases of endotoxemia. LPS caused rapid disappearance of resident peritoneal macrophages, followed by neutrophil accumulation and increased circulating TNF- and IL-6. In the liver, LPS induced inflammatory, acute-phase, and anti-inflammatory transcripts while suppressing genes involved in lipid, cholesterol, and xenobiotic metabolism. Hepatic glutathione was reduced, whereas total superoxide dismutase activity was unchanged. These peripheral responses were followed by transient hypothermia, reduced food intake, and body weight loss. Regional brain mapping showed increased c-Fos labeling in the area postrema, nucleus of the solitary tract, external lateral parabrachial nucleus, paraventricular nucleus of the hypothalamus, and arcuate nucleus. In parallel, LPS selectively promoted IBA1-positive area in the median eminence and arcuate nucleus, whereas several other regions showed no changes, indicating that neuronal and microglial responses are regionally distinct. Behaviorally, LPS reduced locomotion and exploration, increased freezing, and increased forced-swim immobility. Changes in spatial exploration were most pronounced during the acute phase, whereas locomotor suppression and passive stress-coping persisted longer and varied in magnitude with the timing of inflammatory challenge. Together, these findings show that systemic LPS produces a coordinated sickness state in female BALB/c mice that links peripheral inflammation and hepatic metabolic and redox changes with region-specific neuronal and microglial responses, altered thermoregulation and feeding, and behavioral suppression.

Chronic pain is frequently accompanied by anxiety and other affective disturbances, but the molecular and cellular changes linking peripheral injury to persistent alterations in brain function remain incompletely defined. The hippocampal extracellular matrix (ECM) regulates synaptic plasticity, cellular signaling, and neuroimmune interactions and may therefore contribute to pain-related central plasticity. We used a tibial fracture/cast immobilization model to examine temporal changes in hippocampal ECM, glial morphology, and affective behavior following peripheral injury. Behavioral testing was performed at 3, 7, and 20 weeks after injury, while high-dimensional morphometric analysis of microglia and astrocytes was performed at 1, 3, 7, and 20 weeks. Hippocampal ECM associated molecular signals were mapped at the chronic stage using decellularization coupled with MALDI-TOF mass spectrometry imaging. Injured mice developed mechanical hypersensitivity and reduced exploration in two anxiety related paradigms during the early and chronic stages, with these behavioral phenotypes no longer detected at 20 weeks. At 7 weeks, injury was associated with changes in hippocampal ECM-associated peptide signals, including reduced signals corresponding to four ECM-associated proteins. Microglia and astrocytes exhibited distinct, time-dependent changes in density and multidimensional morphology, with some alterations persisting after behavioral measures returned toward control levels. In vitro, BV2 microglia exhibited rigidity-dependent changes in morphology, phagocytic behavior, and calcium signaling. Together, these findings define a temporally evolving hippocampal ECM and glial phenotype following peripheral injury and identify matrix biomechanics as a candidate regulator of microglial function.

Temporal lobe epilepsy (TLE) is frequently associated with severe cognitive impairment and psychiatric comorbidities that are highly disabling and not targeted by anti-seizure medications, highlighting the need for therapies that target epileptogenesis rather than merely suppress seizures. Despite strong evidence implicating neuroinflammation in this process, anti-inflammatory approaches have not yielded such therapies yet. Infiltrating peripheral monocytes are widely viewed as detrimental amplifiers of post-status epilepticus (SE) inflammation, although emerging data suggest context-dependent protective roles. The cannabinoid receptor type 2 (CB2), highly expressed in myeloid cells, represents a potential immunomodulatory target linking leukocyte recruitment and inflammatory polarization. Using a juvenile rat model of TLE, we characterized hippocampal neuroinflammation and CB2 expression during epileptogenesis and evaluated the effects of transient CB2 activation with the selective agonist GP1a. SE induced a rapid but transient inflammatory response and robust recruitment of peripheral monocytes that persisted as anti-inflammatory monocyte-derived macrophages. CB2 activation did not suppress early cytokine induction but selectively enhanced recruitment of anti-inflammatory monocytes and modestly increased anti-inflammatory signaling. Importantly, transient CB2 stimulation preserved synaptic plasticity, improved cognitive performance, reduced anxiety-like behavior, and delayed seizure onset. These findings identify CB2-dependent modulation of peripheral myeloid cells as a potential disease-modifying axis in TLE.

BackgroundTherapeutics that modulate peripheral and central immune responses are emerging as promising approaches for neurodegenerative disease. However, the biological context in which these interventions are deployed may critically influence therapeutic outcomes. An attenuated Brucella melitensis 16M strain and a similar strain engineered to express the metabolite indole have previously demonstrated therapeutic efficacy in preclinical models of cancer and autoimmunity through immune system modulation. Here, we tested whether repeated administration of these bacterial strains could modify pathological outcomes in a mouse model of tauopathy. MethodsAttenuated Brucella strains were administered to transgenic mice overexpressing mutant tau protein on a human APOE4 knock-in background via intraperitoneal injection every 5 weeks starting at 6 months of age. Mice were analyzed at 9.5 months of age for tau pathology, neurodegeneration, and changes in innate and adaptive immune responses. ResultsBrucella strains distributed predominantly in the periphery following repeated intraperitoneal treatment in transgenic mice, with minimal detection in the brain and no detection in the dural meninges. Repeated administration of either bacterial strain was well tolerated, with no evidence of adverse safety events. Surprisingly, repeated treatment with the engineered Brucella strain exacerbated neurodegenerative pathology, resulting in reduced hippocampal volume and increased phosphorylated tau pathology compared with control- and non-engineered Brucella strain -treated animals. Immunohistochemical analyses revealed increased numbers of hippocampal CD4+ T cells following treatment with either Brucella strain relative to PBS controls. However, only treatment with the engineered Brucella increased microglial reactivity within the hippocampus. ConclusionThese findings demonstrate that peripheral administration of an engineered bacterial therapeutic can differentially influence neuroimmune responses and disease progression. These results underscore the importance of disease context when developing bacteria-based immunomodulatory therapies for neurodegenerative disorders.

BackgroundA significant number of people with HIV-1 still experience neurocognitive impairments (NCI), despite effective antiretroviral treatment. HIV-NCI is diverse and multifactorial, with mechanisms that cause its development and progression still not fully understood. We examined early HIV-related changes in brain stability and studied neuroimmune interactions at the single-cell level to better understand how NCI develops. MethodsTo model changes in brain homeostasis, we developed an advanced human iPSC-derived 3D cerebral assembloid model that includes microglia, by co-developing neural progenitor cells with tdTomato-tagged and CD34+ cell-derived microglial precursors. Assembloids were infected with a macrophage R5-tropic HIV-1 strain NL-AD8. Viral spread was measured using a proviral DNA assay, qPCR for HIV RNA, and 3D immunostaining for Tat protein. Single-cell transcriptomics with tdTomato lineage tracing revealed HIV-1 induced disturbances and cell-type-specific responses. The niche net algorithm was used to identify ligand-receptor interactions between microglia and the brain microenvironment during homeostasis and HIV infection. ResultsHighly ramified tdTomato+ IBA-1+ microglia were evenly distributed throughout the assembloids within 15 days of culture. Single-cell transcriptomics identified microglia, excitatory/inhibitory neurons, astrocytes, and oligodendrocyte precursors within the assembloids. Neurons in microglia-containing assembloids upregulated genes related to neurotransmission, synaptogenesis, and neuronal development compared to neurons in organoids without microglia. Niche net analysis showed microglia-derived neurotropic ligands supported neuronal and astrocytic differentiation. The R5-tropic HIV-1 specifically targeted microglia, inducing a reactive phenotype that transmitted interferon and pro-inflammatory signals to nearby cells and increased MHC-I antigen-presentation genes. Notably, neuroprotective ligands from non-glial cells and bystander microglia in the assembloids attempted to counteract HIV-related inflammation and promote neural repair. ConclusionsOur microglia-containing assembloid model replicates in vivo neurodevelopmental interactions, allowing high-resolution analysis of homeostatic and HIV-induced responses across different brain cell types. Homeostatic microglia support neuronal health, while HIV infection triggers a reactive state that spreads inflammatory signals within the brain environment. The presence of multiple glial and non-glial populations uncovered previously unknown crosstalk, including bystander microglial phenotypes and neuroprotective signaling mechanisms that counteract inflammation. These findings emphasize early HIV responses that balance injury and adaptation, offering insights for developing therapies that target microglial activation, boost neuroprotection, and address HIV reservoirs in the brain.

Female sex and the APOEe4 allele are top risk factors for Alzheimers disease (AD). Microglia play a role in the pathogenesis of AD, yet how sex and APOE genotype affect microglia remain poorly understood. Here, we characterized the transcriptomic and morphological profiles in the hippocampus and cortex of microglia from humanized APOEe3 and APOEe4 mice of males and females. The hAPOEe4 genotype was associated with sex-dependent effects on microglia co-expression modules in both brain regions, involving cellular stress and immunometabolism processes. In females, a hippocampal cell cycle module was supported by reduced microglial proliferation. Cortical modules were enriched for lipid metabolism and immune-related processes whose expression decreased in females but increased in male hAPOEe4. Male, but not female, hAPOEe4 microglia shifted toward an ameboid state in both regions. Together, these findings reveal sex-dependent microglial responses to APOEe4 across brain regions and highlight the need to incorporate sex-specific approaches into AD research.

West Nile virus (WNV) is a mosquito-borne orthoflavivirus that causes severe encephalitis, for which no approved antiviral therapies or human vaccines are currently available. Disease-associated microglia (DAM) represent a microglial state associated with neuroprotective functions in neurodegenerative diseases. We previously showed that DAM-like cells are localized in the vicinity of WNV-infected cells in the mouse brain and surmised that these cells may respond to WNV-infected cells. However, the functional significance of this spatial association has since remained unclear. Given the previous reports linking interleukin-34 (IL-34) to the activation of DAM-like cells, we investigated whether IL-34 promotes DAM-like responses and whether these responses are associated with protection against WNV infection. Transcriptomic analysis of IL-34-treated HMC3 human microglial cells revealed upregulation of markers characteristic of DAM, including TREM2, APOE, FABP5, and FTH1. IL-34-treated HMC3 cells suppressed WNV replication in co-culture with WNV-infected SH-SY5Y human neuroblastoma cells apparently in a cell-cell contact-dependent manner, independent of secreted factors. In WNV-infected mice, IL-34 administration improved survival, reduced viral titers, and decreased neuronal apoptosis. IL-34 also increased the abundance of CD11c- and SPP1-positive DAM-like cells, predominantly in the vicinity of WNV-infected cells, in the mouse brain. These findings indicate that IL-34 promotes the activation of DAM-like cells and enhances protective responses in WNV encephalitis. IMPORTANCEWest Nile virus (WNV) is a major cause of viral encephalitis worldwide, with no approved antiviral treatment or human vaccine currently available. Microglia, the resident immune cells of the brain, play key roles in responding to viral infection. However, the mechanism through which specific microglial activation states contribute to protection in viral encephalitis remains poorly understood. In this study, we show that interleukin-34 promotes microglial responses resembling disease-associated microglia (DAM) and is associated with enhanced protection against WNV infection in cell culture and mouse models. The study findings suggest that activation of DAM-like cells may contribute to protective host responses against neurotropic viral infection and provide new insights into the role of specific microglial states in viral encephalitis.

INTRODUCTION: Alzheimer's disease (AD) disproportionately affects women, but the underlying mechanisms are not fully understood. We compare sex-specific molecular changes across AD with and without dementia at single-cell resolution. METHODS: We performed sex-stratified single-nucleus transcriptomic analysis of human AD to dissect sex-specific differences in dementia progression, using the SEA-AD cohort for discovery and the ROSMAP and NBB datasets, together with 5xFAD mouse models, for validation. Donors were classified as no-dementia controls, no-dementia AD, or dementia AD, followed by donor-level pathway analysis, de novo microglial clustering, communication modeling, and cytokine-response enrichment RESULTS: Females with AD dementia showed enhanced inflammatory pathway activity across glial, neuronal and vascular-associated cell types, with the strongest enrichment in microglia. This female-biased program centered on IL6-JAK-STAT3 signaling and increased STAT3 expression in microglia and astrocytes. These results were validated in the ROSMAP and NBB datasets and conserved in the 5xFAD mouse model. Microglial clustering resolved 18 states and revealed sex-divergent disease remodeling, including female-specific expansion of redox-reactive and CD163+ macrophage-primed states. Cell:cell communication analysis identified female-biased TGF{beta}/GRN signaling, male-biased CD99 signaling, and dementia-associated SPP1-integrin communication with the vasculature. Microglial cytokine-response analysis identified IL-2 response as a dementia-associated signature in both sexes, alongside a female-biased IL-17/interferon response and a male-biased IL-7 response. DISCUSSION: These findings identify a disease-emergent, female-biased STAT3-centered neuroinflammatory program in human and mouse AD, linking sex-specific microglial remodeling to cytokine responsiveness and glial-vascular communication. The results suggest that sex-specific changes in neuroinflammation pathways in microglia and other cell types are associated with progression to dementia.

The skull bone marrow axis has recently emerged as an important source of immune cells during neuroinflammation, including in the experimental autoimmune encephalomyelitis (EAE) , the mouse model of multiple sclerosis. The cribriform plate bone marrow (cpBM), is a portion of the ethmoid bone of the skull of mice, and is positioned next to nasal regions. At the cribriform plate olfactory nerves pass through the skull and recent evidence supports that it represents an important immune niche with links to CSF outflow and connections to cpBM. Previous data supports cellular composition of the ethmoid bone marrow in mice is altered in neuroinflammation suggesting it senses inflammatory cues, but the exact nature of these changes is still unclear. Here using scRNAseq and flow cytometry of the ethmoid bone marrow region we test how the region responds to EAE. In addition we also compare the cpBM region with systemic bone marrow in the femur to understand region specific differences. We report that neuroinflammation creates a regulatory response at these sites and implicates the cpBM in controlling these effects. A better understanding of the cribriform niche may offer new treatments for neuroinflammatory disease